IL‐9 Is Essential for ILC2‐Mediated but Not Th2‐ and Th17‐Cell‐Mediated Allergic Airway Inflammation in Mice
Year: 2026
Type: article
Abstract: ABSTRACT Interleukin‐9 (IL‐9) has primarily been associated with type 2 immunity in health and disease. While its impact on innate lymphoid cells (ILC2s) is well known, the cellular targets and mechanisms underlying type 2 immunity remain incompletely understood. In this study, we report the generation of a mouse‐specific anti‐IL‐9 receptor (IL‐9R) antibody, enabling us to accurately map IL‐9R protein expression across various immune cell types. In naïve mice, IL‐9R was detectable in ILC2s, marginal zone B cells, and B1b cells. In allergic lung inflammation, a subset of CD4 + T cells faintly upregulated IL‐9R, whereas DCs, macrophages, eosinophils, and neutrophils remained IL‐9R‐negative. Functionally, IL‐9R was found to significantly contribute to ILC2 expansion, their effector cytokine production, and eosinophilia in the papain asthma model. However, in the context of acute and chronic HDM exposure, IL‐9R was dispensable for both allergic lung inflammation and CD4‐dependent memory‐type 2 responses. Using mixed bone marrow chimeras in which IL‐9R is selectively absent in T cells, we confirmed that IL‐9R signaling in T cells does not critically impact chronic Th2 and Th17 responses. Lastly, using mice selectively lacking ILC2s, we demonstrate that this population is the culprit of pathological type 2 immunity in the lung in both papain‐ and acute HDM‐induced asthma models. Together, our results establish that IL‐9 is a critical regulator of ILC2‐dependent type 2 immunity, while its effects on T cell‐dependent responses are minimal. These findings provide a foundation for future studies exploring the therapeutic modulation of IL‐9 signaling in allergy and other inflammatory diseases.
Source: European Journal of Immunology
DOI: 10.1002/eji.70270
Language: English
Topic: IL-33, ST2, and ILC Pathways
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,550
OpenAlex ID: W7204143261
